Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

FRAUNHOFFER, NICOLAS ALEJANDRO; ABUELAFIA, ANALÍA MEILERMAN; CHANEZ, BRICE; BIGONNET, MARTIN; GAYET, ODILE; ROQUES, JULIE; CHULUYAN, EDUARDO; DUSETTI, NELSON; IOVANNA, JUAN

Cancer Communications

Wiley-Blackwell

Año: 2022

2523-3548

Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity